Table 4 GPA and MPA incident patients’ treatments during the induction and maintenance phases, by inclusion period

Induction phases in patients with at least one induction phase

Number of patients

N = 610

N = 620

N = 251

N = 444

N = 903

N = 1,144

Glucocorticoids

591 (96.9%)

582 (93.9%)

0.012

239 (95.2%)

425 (95.7%)

0.758

869 (96.2%)

1,084 (94.8%)

0.112

Cyclophosphamide

316 (51.8%)

289 (46.6%)

0.069

106 (42.2%)

207 (46.6%)

0.264

443 (49.1%)

523 (45.7%)

0.133

Rituximab

59 (9.7%)

171 (27.6%)

< 0.001

15 (6.0%)

89 (20.1%)

< 0.001

76 (8.4%)

281 (24.6%)

< 0.001

Azathioprine

178 (29.2%)

82 (13.2%)

< 0.001

72 (28.7%)

66 (14.9%)

< 0.001

267 (29.6%)

160 (14.0%)

< 0.001

Methotrexate

51 (8.4%)

65 (10.5%)

0.203

7 (2.8%)

10 (2.3%)

0.660

60 (6.6%)

79 (6.9%)

0.816

Mycophenolate mofetil

25 (4.1%)

25 (4.0%)

0.953

21 (8.4%)

22 (5.0%)

0.073

50 (5.5%)

49 (4.3%)

0.189

Plasma exchange

108 (17.7%)

143 (23.1%)

0.020

61 (24.3%)

99 (22.3%)

0.546

179 (19.8%)

261 (22.8%)

0.102

Maintenance phases in patients with at least one maintenance phase

Number of patients

N = 667

N = 635

N = 262

N = 433

N = 973

N = 1,145

Glucocorticoids

655 (98.2%)

625 (98.4%)

0.754

260 (99.2%)

423 (97.7%)

0.129

958 (98.5%)

1,123 (98.1%)

0.506

Rituximab

84 (12.6%)

289 (45.5%)

< 0.001

26 (9.9%)

177 (40.9%)

< 0.001

116 (11.9%)

498 (43.5%)

< 0.001

Azathioprine

256 (38.4%)

133 (20.9%)

< 0.001

105 (40.1%)

124 (28.6%)

0.002

380 (39.1%)

278 (24.3%)

< 0.001

Methotrexate

83 (12.4%)

75 (11.8%)

0.727

12 (4.6%)

13 (3.0%)

0.279

97 (10.0%)

92 (8.0%)

0.120

Mycophenolate mofetil

54 (8.1%)

31 (4.9%)

0.019

30 (11.5%)

42 (9.7%)

0.463

89 (9.2%)

78 (6.8%)

0.047